Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820470 | 0.83 | CYP3A4 (0.57) | CYP3A4CYP2A6MAPK1MAPTLMNA | |
| SCHEMBL13729667 | 0.81 | CA12 (0.43) | CYP3A4CYP2A6MAPK1MAPTHPGD | |
| SCHEMBL3820950 | 0.75 | HPGD (0.54) | CYP3A4CYP2A6MAPK1MAPTLMNA | |
| SCHEMBL6273762 | 0.75 | PLAU (0.59) | CYP3A4MAPK1MAPTLMNAAPEX1 | |
| SCHEMBL1536330 | 0.75 | PLAU (0.54) | CYP3A4MAPK1MAPTLMNAAPEX1 | |
| SCHEMBL10426539 | 0.74 | MAPT (0.45) | CYP3A4MAPK1MAPTLMNAAPEX1 | |
| SCHEMBL5583766 | 0.74 | SETDB1 (0.53) | CYP3A4CYP2A6MAPK1MAPTSETDB1 | |
| SCHEMBL20554725 | 0.73 | CYP3A4 (0.49) | CYP3A4CYP2A6MAPK1MAPTSETDB1 | |
| SCHEMBL15814879 | 0.73 | CYP3A4 (0.49) | CYP3A4CYP2A6MAPK1MAPTLMNA | |
| SCHEMBL4371294 | 0.73 | HPGD (0.56) | CYP3A4CYP2A6MAPK1SETDB1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | CYP3A4 455/4885CYP2A6 473/4885MAPK1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.